Skip to content

Princess® RICH for the Correction of Fine Lines

A Prospective Open-label, Multicenter Study Evaluating Princess® RICH in Correction of Fine Lines

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03923634
Acronym
RICH
Enrollment
102
Registered
2019-04-22
Start date
2018-10-16
Completion date
2019-10-22
Last updated
2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lateral Canthal Lines, Perioral Rhytids

Brief summary

Eligible subjects deemed by the treating physician to have sufficient severity to merit treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will be treated with Princess® RICH at the Baseline visit and at week 3 and 6.

Interventions

DEVICEPrincess® RICH

Princess® RICH is injected into lateral canthal lines and/or perioral rhytids

Sponsors

Croma-Pharma GmbH
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects deemed by the treating physician to have LCL and/or PR of sufficient baseline severity to merit treatment with Princess® RICH to be corrected * A negative urine pregnancy test at Visit 1 and commitment to use an adequate method of birth control for the duration of the clinical investigation (for women of childbearing potential only.) * Healthy skin in the facial area and free of diseases that could interfere in cutaneous aging evaluation * Willingness to abstain from any aesthetic or surgical procedures in the treatment area for the duration of the clinical investigation * Written signed and dated informed consent

Exclusion criteria

* Tendency to hypertrophic scars, pigment disorders or keloid formation. * History of autoimmune disease or receiving therapy for modification of immune response * Hypersensitivity to hyaluronic acid or glycerol. * Permanent fillers in the areas to be treated. * Subjects who are pregnant or breast feeding. * Subjects who are anticoagulated or with history of bleeding disorder. * Daily treatment with platelet aggregation inhibitors unless previously cleared by their primary care physician. * Cutaneous, inflammatory and/or infectious processes present at V0, recurrent herpes simplex or (pre) cancerous lesions in the areas to be treated * Known Diabetes mellitus or uncontrolled systemic diseases in the assessment of the investigator. * Laser therapy, chemical peeling, dermabrasion or botulin toxin treatment in the area to be treated within less than three months prior to and during the course of the study. * Current participation in another clinical investigation * Subjects whose participation in clinical trials is prohibited by the Austrian Medical Devices Act (e.g, persons with a legal custodian appointed due to mental disability, prisoners, soldiers and other members of the armed forces, civil servants)

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness of Princess® RICH to correct fine lines on the face including lateral canthal lines (LCL) and perioral rhytids (PR)Week 8 compared to BaselinePercentage of responders at week 8 Responder is defined as at least improved versus baseline in the fine lines of lateral canthal lines (LCL) and/or perioral rhytids (PR) assessed with the GAIS (Gloabel Aesthetic Improvement Scale) Global aesthetic improvement can be rated as 'very much improved', 'much improved', 'improved', 'no change' or 'worse

Secondary

MeasureTime frameDescription
Effectiveness of Princess® RICH to correct fine lines on the face including lateral canthal lines (LCL) and perioral rhytids (PR)Week 12 and 16 compared to BaselinePercentage of responders at week 12 and 16.
Ability of Princess® RICH to improve skin hydrationWeek 3, 6, 8, 12 and 16 compared to BaselineChange from baseline at weeks 3, 6, 8, 12 and 16 in skin hydration. Skin hydration is measured using a corneometer device.
Ability of Princess® RICH to improve skin elasticityWeek 3, 6, 8, 12 and 16 compared to BaselineChange from baseline at weeks 3, 6, 8, 12 and 16 in skin elasticity. Skin elasticity is measured using a cutometer device.
Subject satisfaction with treatmentWeek 8, 12 and 16Subject satisfaction with treatment at weeks 8, 12 and 16. Satisfaction with the treatment will be graded using one of the following categories: Very unsatisfied, Unsatisfied, Neither unsatisfied nor satisfied, Satisfied, or Very satisfied.
Ability of Princess® RICH to improve skin toneWeek 3, 6, 8, 12 and 16 compared to BaselineChanges from baseline at weeks 3, 6, 8, 12 and 16 in skin tone. Skin tone is measured using a cutometer device.

Other

MeasureTime frameDescription
Ocurrence and frequency of adverse eventsThroughout the study (16 weeks)Assessment of occurrence and frequency of adverse events

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026